Abstract
Cardiac hypertrophy is the heart’s response to increased work, pressure, or volume overload. It begins with a compensatory phase that allows the heart to meet imposed demand through rapid expression of stress response genes. A decompensatory phase follows marked by additional adaptive stress response gene expression that with prolonged stress progressively turns maladaptive, leading the heart into failure. The transition from compensatory to decompensatory hypertrophy is likely to reflect changes in the transcription factors and regulatory molecules that control these programs in response to changes in stress stimuli and the status of cardiomyocytes throughout the hypertrophic process. Our laboratory has been studying the role of one such transcriptional regulatory molecule, CLP-1 (cardiac lineage protein-1), in the cellular response to hypertrophic stimuli. CLP-1, the mouse homolog of the human HEXIM1 gene, is an inhibitor of P-TEFb (transcription elongation factor b), a component of the transcriptional apparatus that controls RNA polymerase II activity and gene transcription. Knockout of the CLP-1 gene results in a severe form of hypertrophy in fetal mice suggesting that in the absence of the CLP-1 inhibitor, uninhibited P-TEFb activity may lead to unregulated expression of stress response genes and decompensatory hypertrophy. Because of its critical role in regulating the stress gene response to hypertrophic stimuli, we review our laboratory’s work on CLP-1, its control of P-TEFb under various hypertrophic conditions, and how it may play an important role in a novel gene control mechanism, called promoter proximal pausing, that ensures the rapid expression of stress response genes in response to hypertrophic stimuli.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Luptak I, Balschi JA, Xing Y, et al. Decreased contractile and metabolic reserve in peroxisome proliferator-activated receptor-alpha-null hearts can be rescued by increasing glucose transport and utilization. Circulation. 2005;112:2339–46.
Ingwall JS. Energy metabolism in heart failure and remodeling. Cardiovasc Res. 2009;81:412–9.
Eghbali M, Weber KT. Collagen and the myocardium: fibrillar structure, biosynthesis and degradation in relation to hypertrophy and its regression. Mol Cell Biochem. 1990;96:1–14.
Boluyt MO, O’Neill L, Meredith AL, et al. Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure. Marked upregulation of genes encoding extracellular matrix components. Circ Res. 1994;75:23–32.
Mujumdar VS, Tyagi SC. Temporal regulation of extracellular matrix components in transition from compensatory hypertrophy to decompensatory heart failure. J Hypertens. 1999;17:261–70.
Ho CY, Lopez B, Coelho-Filho OR, et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med. 2010;363:552–63.
Dorn 2nd GW. Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodeling. Cardiovasc Res. 2009;81:465–73.
van Empel VP, Bertrand AT, Hofstra L, et al. Myocyte apoptosis in heart failure. Cardiovasc Res. 2005;67:21–9.
Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signaling pathways. Nat Rev Mol Cell Biol. 2006;7:589–600.
Rose BA, Force T, Wang Y. Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol Rev. 2010;90:1507–46.
Clerk A, Cullingford TE, Fuller SJ, et al. Signaling pathways mediating cardiac myocyte gene expression in physiological and stress responses. J Cell Physiol. 2007;212:311–22.
Kehat I, Molkentin JD. Extracellular signal-regulated kinase 1/2 (ERK1/2) signaling in cardiac hypertrophy. Ann NY Acad Sci. 2010;1188:96–102.
Black FM, Packer SE, Parker TG, et al. The vascular smooth muscle alpha-actin gene is reactivated during cardiac hypertrophy provoked by load. J Clin Invest. 1991;88:1581–8.
Bernardo BC, Weeks KL, Pretorius L, et al. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther. 2010;128: 191–227.
Lehman JJ, Kelly DP. Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth. Heart Fail Rev. 2002;7:175–85.
Mann DL. Mechanisms and models in heart failure: a combinatorial approach. Circulation. 1999;100:999–1008.
Ghatpande S, Goswami S, Mathew S, et al. Identification of a novel cardiac lineage-associated protein(cCLP-1): a candidate regulator of cardiogenesis. Dev Biol. 1999;208:210–21.
Huang F, Wagner M, Siddiqui MA. Structure, expression, and functional characterization of the mouse CLP-1 gene. Gene. 2002;292:245–59.
Rice AP. Dysregulation of positive transcription elongation factor B and myocardial hypertrophy. Circ Res. 2009;104:1327–9.
Huang F, Wagner M, Siddiqui MA. Ablation of the CLP-1 gene leads to down-regulation of the HAND1 gene and abnormality of the left ventricle of the heart and fetal death. Mech Dev. 2004;121:559–72.
Espinoza-Derout J, Wagner M, Shahmiri K, et al. Pivotal role of cardiac lineage protein-1 (CLP-1) in transcriptional elongation factor P-TEFb complex formation in cardiac hypertrophy. Cardiovasc Res. 2007;75:129–38.
Espinoza-Derout J, Wagner M, Salciccioli L, et al. Positive transcription elongation factor b activity in compensatory myocardial hypertrophy is regulated by cardiac lineage protein-1. Circ Res. 2009;104:1347–54.
Yik JH, Chen R, Nishimura R, et al. Inhibition of P-TEFb (CDK9/Cyclin T) kinase and RNA polymerase II transcription by the coordinated actions of HEXIM1 and 7SK snRNA. Mol Cell. 2003;12:971–82.
Dey A, Chao SH, Lane DP. HEXIM1 and the control of transcription elongation: from cancer and inflammation to AIDS and cardiac hypertrophy. Cell Cycle. 2007;6:1856–63.
Michels AA, Nguyen VT, Fraldi A, et al. MAQ1 and 7SK RNA interact with CDK9/cyclin T complexes in a transcription-dependent manner. Mol Cell Biol. 2003;23:4859–69.
Peterlin BM, Price DH. Controlling the elongation phase of transcription with P-TEFb. Mol Cell. 2006;23:297–305.
Price DH. Poised polymerases: on your mark…get set…go! Mol Cell. 2008;30(1):7–10.
Kohoutek J. P-TEFb- the final frontier. Cell Div. 2009;4:19.
Core LJ, Lis JT. Transcription regulation through promoter-proximal pausing of RNA polymerase II. Science. 2008;319:1791–2.
Thattaliyath BD, Livi CB, Steinhelper ME, et al. HAND1 and HAND2 are expressed in the adult-rodent heart and are modulated during cardiac hypertrophy. Biochem Biophys Res Commun. 2002;297:870–5.
Sano M, Abdellatif M, Oh H, et al. Activation and function of cyclin T-Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy. Nat Med. 2002;8:1310–7.
Yang Z, Zhu Q, Luo K, et al. The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription. Nature. 2001;414:317–22.
Nguyen VT, Kiss T, Michels AA, et al. 7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes. Nature. 2001;414:322–5.
Michels AA, Fraldi A, Li Q, et al. Binding of the 7SK snRNA turns the HEXIM1 protein into a P-TEFb (CDK9/cyclin T) inhibitor. EMBO J. 2004;23:2608–19.
Molkentin JD, Lu JR, Antos CL, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93:215–28.
Semeniuk LM, Severson DL, Kryski AJ, Swirp SL, Molkentin JD, Duff HJ. Time-dependent systolic and diastolic function in mice overexpressing calcineurin. Am J Physiol Heart Circ Physiol. 2003;284:H425–30.
Zeitlinger J, Stark A, Kellis M, et al. RNA polymerase stalling at developmental control genes in the Drosophila melanogaster embryo. Nat Genet. 2007;39:1512–6.
Fujinaga K, Irwin D, Huang Y, et al. Dynamics of human immunodeficiency virus transcription: P-TEFb phosphorylates RD and dissociates negative effectors from the transactivation response element. Mol Cell Biol. 2004;24:787–95.
Yamada T, Yamaguchi Y, Inukai N, et al. P-TEFb-mediated phosphorylation of hSpt5 C-terminal repeats is critical for processive transcription elongation. Mol Cell. 2006;21:227–37.
Chen R, Liu M, Li H, et al. PP2B and PP1alpha cooperatively disrupt 7SK snRNP to release P-TEFb for transcription in response to Ca2+ signaling. Genes Dev. 2008;22:1356–68.
Contreras X, Barboric M, Lenasi T, et al. HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription. PLoS Pathog. 2007;3:1459–69.
Fujita T, Ryser S, Piuz I, et al. Up-regulation of P-TEFb by the MEK1-extracellular signal-regulated kinase signaling pathway contributes to stimulated transcription elongation of immediate early genes in neuroendocrine cells. Mol Cell Biol. 2008;28:1630–43.
Yamauchi-Takihara K. gp130-mediated pathway and heart failure. Future Cardiol. 2008;4(4):427–37.
Wagner M, Siddiqui MA. Signaling networks regulating cardiac myocyte survival and death. Curr Opin Investig Drugs. 2009;10:928–37.
Beckles DL, Mascareno E, Siddiqui MA. Inhibition of Jak2 phosphorylation attenuates pressure overload cardiac hypertrophy. Vascul Pharmacol. 2006;45:350–7.
Hou T, Ray S, Brasier AR. The functional role of an interleukin 6-inducible CDK9.STAT3 complex in human gamma-fibrinogen gene expression. J Biol Chem. 2007;282:37091–102.
Zhou Q, Yik JH. The Yin and Yang of P-TEFb regulation: implications for human immunodeficiency virus gene expression and global control of cell growth and differentiation. Microbiol Mol Biol Rev. 2006;70:646–59.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Siddiqui, M.A.Q., Wagner, M., Espinoza-Derout, J., Huang, F., Beckles, D., Mascareno, E. (2011). CLP-1-Mediated Transcriptional Control of Hypertrophic Gene Programs Underlying Cardiac Hypertrophy. In: Ostadal, B., Nagano, M., Dhalla, N. (eds) Genes and Cardiovascular Function. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-7207-1_19
Download citation
DOI: https://doi.org/10.1007/978-1-4419-7207-1_19
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-7206-4
Online ISBN: 978-1-4419-7207-1
eBook Packages: MedicineMedicine (R0)